Advances in treatment of diabetic kidney disease with butyrate

doi:10.3877/cma.j.issn.1674-0785.2024.03.011

Abstract

Abstract:

Diabetic kidney disease is one of the most common chronic microvascular complications of diabetes mellitus, and current conventional treatments can not completely delay its onset and progression. Therefore, the development of new drugs to treat diabetic kidney disease and improve renal function has become an active area of research. In recent years, it has been found that the abundance of butyrate-producing bacteria is significantly reduced in patients with diabetic kidney disease, and butyrate production is reduced. As a key transmitter of the gut-renal axis, butyrate ameliorates and attenuates diabetic kidney injury by activating G protein-coupled receptors, inhibiting histone deacetylase, regulating non-coding RNA expression, inducing histone butyrylation, and regulating cellular autophagy. The aim of this review is to explore the role of butyrate in ameliorating diabetic kidney injury and the related therapeutic strategies for restoring intestinal butyrate levels, which will provide a reference for the study of the pathogenesis and treatment of diabetic kidney disease.

Key words: Diabetic kidney disease, Butyrate, Gut microbiota, Short-chain fatty acids

Lu Bai, Qingxia Li, Yizhuo Feng, Xueqian Liu, Ruoqi Liu, Zhuomin Qu, Lingxia Zhao. Advances in treatment of diabetic kidney disease with butyrate[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(03): 303-308.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2024.03.011

https://zhlcyszz.cma-cmc.com.cn/EN/Y2024/V18/I03/303

References 57

8	Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing [J]. Nature, 2010,464(7285): 59-65.
9	Shine EE, Crawford JM. Molecules from the microbiome [J]. Annu Rev Biochem, 2021,90: 789-815.
10	Evenepoel P, Poesen R, Meijers B. The gut-kidney axis [J]. Pediatr Nephrol, 2017,32(11): 2005-2014.
11	Han S, Chen M, Cheng P, et al. A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals [J]. Front Endocrinol (Lausanne), 2022,13: 1018093.
12	Shang J, Cui W, Guo R, et al. The harmful intestinal microbial community accumulates during DKD exacerbation and microbiome-metabolome combined validation in a mouse model [J]. Front Endocrinol (Lausanne), 2022,13: 964389.
13	Cai K, Ma Y, Cai F, et al. Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury [J]. Endocrine, 2022,76(2): 294-303.
14	Li Y, Qin GQ, Wang WY, et al. Short chain fatty acids for the risk of diabetic nephropathy in type 2 diabetes patients [J]. Acta Diabetol, 2022,59(7): 901-909.
15	Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood [J]. Gut, 1987,28(10): 1221-1227.
16	Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data [J]. mBio, 2014,5(2): e00889.
17	Boets E, Gomand SV, Deroover L, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study [J]. J Physiol, 2017,595(2): 541-555.
18	Pryde SE, Duncan SH, Hold GL, et al. The microbiology of butyrate formation in the human colon [J]. FEMS Microbiol Lett, 2002,217(2): 133-139.
19	Yan M, Li X, Sun C, et al. Sodium butyrate attenuates AGEs-induced oxidative stress and inflammation by inhibiting autophagy and affecting cellular metabolism in THP-1 cells [J/OL]. Molecules (Basel, Switzerland), 2022,27(24): 8715.
20	Sun J, Wang Y, Cui W, et al. Role of epigenetic histone modifications in diabetic kidney disease involving renal fibrosis [J]. J Diabetes Res, 2017,2017: 7242384.
21	Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease [J]. Adv Immunol, 2014,121: 91-119.
22	Khan S, Jena G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-β1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats [J]. Food Chem Toxicol, 2014,73: 127-139.
23	Dong W, Jia Y, Liu X, et al. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC [J]. J Endocrinol, 2017,232(1): 71-83.
24	Du Y, Tang G, Yuan W. Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HG‑induced NRK‑52E cells [J]. Int J Mol Med, 2020,45(1): 210-222.
1	Boughton CK, Tripyla A, Hartnell S, et al. Publisher Correction: Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial [J/OL]. Nature Medicine, 2021,27(10): 1850-1850.
2	杨莉, 迟春花, 吕继成, 等. 中国糖尿病肾脏病基层管理指南 [J]. 中华全科医师杂志, 2023,22(2): 146-157.
3	Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes Atlas, 9th edition [J]. Diabetes Res Clin Pract, 2019,157: 107843.
4	Kawanami D, Matoba K, Utsunomiya K. Signaling pathways in diabetic nephropathy [J]. Histol Histopathol, 2016,31(10): 1059-1067.
5	Zhong C, Dai Z, Chai L, et al. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease [J]. J Clin Lab Anal, 2021,35(12): e24062.
6	Zhang L, Wang Z, Zhang X, et al. Alterations of the gut microbiota in patients with diabetic nephropathy [J]. Microbiol Spectr, 2022,10(4): e0032422.
7	叶凯丽, 黄诗琴, 胡婷, 等. 丁酸盐对糖尿病肾病小鼠肾损伤的保护作用及机制 [J]. 温州医科大学学报, 2023,53(1): 42-48.
25	Miyamoto J, Hasegawa S, Kasubuchi M, et al. Nutritional signaling via free fatty acid receptors [J]. Int J Mol Sci, 2016,17(4): 450.
26	Cheng X, Zhou T, He Y, et al. The role and mechanism of butyrate in the prevention and treatment of diabetic kidney disease [J]. Front Microbiol, 2022,13: 961536.
27	Huang W, Man Y, Gao C, et al. Short-chain fatty acids ameliorate diabetic nephropathy via GPR43-mediated inhibition of oxidative stress and NF-κB signaling [J]. Oxid Med Cell Longev, 2020,2020: 4074832.
28	Macia L, Tan J, Vieira AT, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome [J]. Nat Commun, 2015,6: 6734.
29	Feng W, Wu Y, Chen G, et al. Sodium butyrate attenuates diarrhea in weaned piglets and promotes tight junction protein expression in colon in a GPR109A-dependent manner [J]. Cell Physiol Biochem, 2018,47(4): 1617-1629.
30	Li YJ, Chen X, Kwan TK, et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A [J]. J Am Soc Nephrol, 2020,31(6): 1267-1281.
31	Ren H, Wang Q. Non-coding RNA and diabetic kidney disease [J]. DNA Cell Biol, 2021,40(4): 553-567.
32	Belcheva A. MicroRNAs at the epicenter of intestinal homeostasis [J]. Bioessays, 2017,39(3).
33	毛玉熠, 李格菲, 韩睿. microRNAs调控糖尿病肾病发展的研究进展 [J/OL]. 中华临床医师杂志(电子版), 2021,15(2): 133-138.
34	Du Y, Yang YT, Tang G, et al. Butyrate alleviates diabetic kidney disease by mediating the miR-7a-5p/P311/TGF-β1 pathway [J]. FASEB J, 2020,34(8): 10462-10475.
35	Zhang P, Sun Y, Peng R, et al. Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3 [J]. Cell Death Dis, 2019,10(7): 526.
36	Yang H, Zhang Z, Peng R, et al. RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models [J]. Biosci Rep, 2021,41(4): BSR20203005.
37	Lin TA, Wu VC, Wang CY. Autophagy in chronic kidney diseases [J]. Cells, 2019,8(1): 61.
38	Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research [J/OL]. Cell, 2010,140(3): 313-326.
39	Lou D, Zhang X, Jiang C, et al. 3β,23-Dihydroxy-12-ene-28-ursolic acid isolated from cyclocarya paliurus alleviates NLRP3 inflammasome-mediated gout via PI3K-AKT-mTOR-dependent autophagy [J]. Evid Based Complement Alternat Med, 2022,2022: 5541232.
40	Ma X, Wang Q. Short-chain fatty acids attenuate renal fibrosis and enhance autophagy of renal tubular cells in diabetic mice through the HDAC2/ULK1 axis [J]. Endocrinol Metab (Seoul), 2022,37(3): 432-443.
41	Ruiz-Andres O, Sanchez-Niño MD, Cannata-Ortiz P, et al. Histone lysine crotonylation during acute kidney injury in mice [J]. Dis Model Mech, 2016,9(6): 633-645.
42	Chen Y, Sprung R, Tang Y, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones [J]. Mol Cell Proteomics, 2007,6(5): 812-819.
43	Luo W, Yu Y, Wang H, et al. Up-regulation of MMP-2 by histone H3K9 β-hydroxybutyrylation to antagonize glomerulosclerosis in diabetic rat [J]. Acta Diabetol, 2020,57(12): 1501-1509.
44	欧阳琳, 王燕飞, 侯粲. 组蛋白翻译后修饰在糖尿病肾病发病中的作用 [J]. 中华肾脏病杂志, 2015,31(7): 553-556.
45	Zhou T, Xu H, Cheng X, et al. Sodium butyrate attenuates diabetic kidney disease partially via histone butyrylation modification [J]. Mediators Inflamm, 2022,2022: 7643322.
46	Luo L, Luo J, Cai Y, et al. Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy [J]. Pharmacol Res, 2022,183: 106367.
47	Carvalho CM, Gross LA, de Azevedo MJ, et al. Dietary fiber intake (supplemental or dietary pattern rich in fiber) and diabetic kidney disease: A systematic review of clinical trials [J]. Nutrients, 2019,11(2): 347.
48	Ni Y, Zheng L, Nan S, et al. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota [J]. Acta Biochim Biophys Sin (Shanghai), 2022,54(10): 1406-1420.
49	Zhu H, Cao C, Wu Z, et al. casei Zhang slows the progression of acute and chronic kidney disease [J]. Cell Metab, 2021,33(10): 1926-1942.e8.
50	Yang J, Li Y, Wen Z, et al. Oscillospira - a candidate for the next-generation probiotics [J]. Gut Microbes, 2021,13(1): 1987783.
51	Zaky A, Glastras SJ, Wong MYW, et al. The role of the gut microbiome in diabetes and obesity-related kidney disease [J]. Int J Mol Sci, 2021,22(17): 9641.
52	Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition [J]. Cell Metab, 2017,26(4): 611-619.e6.
53	Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome [J]. Gastroenterology, 2012,143(4): 913-6.e7.
54	Bastos RMC, Simplício-Filho A, Sávio-Silva C, et al. Fecal microbiota transplant in a pre-clinical model of type 2 diabetes mellitus, obesity and diabetic kidney disease [J]. Int J Mol Sci, 2022,23(7): 3842.
55	Hu ZB, Lu J, Chen PP, et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis [J]. Theranostics, 2020,10(6): 2803-2816.
56	Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes [J]. Diabetes, 2015,64(5): 1794-1803.
57	Han C, Zhang X, Pang G, et al. Hydrogel microcapsules containing engineered bacteria for sustained production and release of protein drugs [J]. Biomaterials, 2022,287: 121619.

[1]	Yingying Kong, Lutao Xie, Xiaochi Lu, Jiefeng Xu, Guangju Zhou, Mao Zhang. Protective effect and mechanism of sodium butyrate on cardio-brain injury after cardiac arrest resuscitation in pigs [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2023, 16(05): 355-362.
[2]	Shiyang Yu, Dagang Yang, Yongning Li, Xianqiu Xiong, Futang Li, Rong Wang. Accelerated rehabilitation surgery in obstructive jaundice：metabolic interactions between bile acids and intestinal microbes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 230-234.
[3]	Wenqi Lu, Yanru Zhao, Huandi Li, Xinna Fan, Jia Wang, Ping Li. Serum expression of SMAD2 and SOX6 in patients with type 2 diabetes mellitus and their relationship with proteinuria [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 145-151.
[4]	Jingxuan Shi, Yuanyuan Jiao, Jingwei Tian, Li Zhuo. Efficacy of mesenchymal stem cells-derived exosomes in the treatment of diabetic kidney disease in animals: a meta-analysis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 79-86.
[5]	Xinxin Hu, Xiaofan Meng, Zhaoan Guo. Research progress on the pathogenesis of hypertensive nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(06): 339-343.
[6]	Xiaomei Qiao, Kaili Kong, Jingai Fang, Xiaodong Zhang. Research progress on the relationship between the "gut-skin axis" and the uremic skin lesions [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 291-294.
[7]	Na Li, Guozhen Zhu. Progress of research on the roles of gut microbiota and its metabolites in acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 215-219.
[8]	Li Cheng, Xiaoliang Zhang. Relationship between serum uric acid combining cystatin C and diabetic kidney disease in patients with diabetic retinopathy and influencing factors [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 194-199.
[9]	Ning Wang, Yanzhe Liu, Ziying Wu, Chao Zeng, Guanghua Lei, Tingting Sha, Yilun Wang. Causal associations of gut Microbiota with phenotype indicators of sarcopenia: A mendelian randomization study [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(06): 333-342.
[10]	Xiao Qu, Liang Wang, Ping Lu, Bin He, Min Sun. Correlation analysis of inflammatory factors in peripheral blood and characteristics of Gut microbiota with the condition of patients with active Ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 466-470.
[11]	Meiju Wei, Ling Pan. Role of gut microbiota-bile acid metabolism axis in chronic kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 219-222.
[12]	Ying Tan, Pengfei Zhu, Nan Li, Liji Huang, Xiqiao Zhou, Qianhua Yan, Jiangyi Yu. Effectiveness of Huobahuagen tablets in combination with Huangkui capsules in diabetic kidney disease patients with high or extremely high risk of disease progression [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 171-177.
[13]	Liji Huang, Ting Wang, Pengfei Zhu, Jingshun Liu, Jiangyi Yu, Shaofeng Xie. Qikui granules combined with Huobahuagen tablets for treatment of stage G3A3 diabetic kidney disease: clinical efficacy and impact on serum microRNA-21 [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1247-1252.
[14]	Daya Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Da Li, Feihu Bai. Role of intestinal microecological dysregulation in development of metabolic-associated fatty liver disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 828-833.
[15]	Zeping Jin, Jing Dong, Yunpeng Liu, Yang Wang. Correlation between microbiota-gut-brain axis and the risk factors of ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 510-517.

Please choose a citation manager

Content to export